J L Mulshine

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Lung cancer evolution to preinvasive management
    James L Mulshine
    Intervention Section, Medicine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Clin Chest Med 23:37-48. 2002
  2. ncbi request reprint Lung cancer chemoprevention: moving from concept to a reality
    James L Mulshine
    Intervention Section, Cell and Cancer Biology Branch, Center for Cancer Research, National Cancer Institute, National Institutes for Health, Bethesda, MD 20892 1906, USA
    Lung Cancer 41:S163-74. 2003
  3. pmc Recent molecular advances in the approach to early lung cancer detection and intervention
    J L Mulshine
    Division of Clinical Science, National Cancer Institute, Rockville, Maryland 20850 3300, USA
    Environ Health Perspect 105:935-9. 1997
  4. ncbi request reprint Differential expression of the early lung cancer detection marker, heterogeneous nuclear ribonucleoprotein-A2/B1 (hnRNP-A2/B1) in normal breast and neoplastic breast cancer
    J Zhou
    Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Breast Cancer Res Treat 66:217-24. 2001
  5. ncbi request reprint Biochemical characterization of peptide alpha-amidation enzyme activities of human neuroendocrine lung cancer cell lines
    A M Treston
    Intervention Section, National Cancer Institute Division of Cancer Prevention and Control, Rockville, Maryland 20850
    Cell Growth Differ 4:911-20. 1993
  6. ncbi request reprint Lipoxygenase inhibitors prevent lung carcinogenesis and inhibit non-small cell lung cancer growth
    T W Moody
    Cell and Cancer Biology Department, National Cancer Institute, Rockville, Maryland, USA
    Exp Lung Res 24:617-28. 1998
  7. ncbi request reprint Moving to the routine management of pre symptomatic lung cancer
    J L Mulshine
    Intervention Section, Center for Cancer Research, NCI, NIH, Bethesda, MD 20850, USA
    Lung Cancer 34:S1-5. 2001
  8. ncbi request reprint Five-lipoxygenase inhibitors can mediate apoptosis in human breast cancer cell lines through complex eicosanoid interactions
    I Avis
    Intervention Section, Department of Cell and Cancer Biology, Division of Clinical Sciences, National Cancer Institute, NIH Clinical Center, 9000 Rockville Pike, Bethesda, MD 20892-1906, USA
    FASEB J 15:2007-9. 2001
  9. ncbi request reprint Reducing lung cancer risk: early detection
    J L Mulshine
    Department of Cell and Cancer Biology, Medicine Branch, Division of Clinical Science, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1906, USA
    Chest 116:493S-496S. 1999
  10. ncbi request reprint Expression of heterogeneous nuclear ribonucleoprotein A2/B1 changes with critical stages of mammalian lung development
    L M Montuenga
    Cell and Cancer Biology Department, Medicine Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Am J Respir Cell Mol Biol 19:554-62. 1998

Detail Information

Publications37

  1. ncbi request reprint Lung cancer evolution to preinvasive management
    James L Mulshine
    Intervention Section, Medicine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Clin Chest Med 23:37-48. 2002
    ..Further sustained efforts will be required to define the true value of these new approaches through clinical trials as the specialty moves responsibly to routine preventative care of individuals at risk for lung cancer...
  2. ncbi request reprint Lung cancer chemoprevention: moving from concept to a reality
    James L Mulshine
    Intervention Section, Cell and Cancer Biology Branch, Center for Cancer Research, National Cancer Institute, National Institutes for Health, Bethesda, MD 20892 1906, USA
    Lung Cancer 41:S163-74. 2003
    ..The paper describes approaches to tailor chemoprevention development specifically to the biological, pharmacological and anatomical realities of this most lethal cancer...
  3. pmc Recent molecular advances in the approach to early lung cancer detection and intervention
    J L Mulshine
    Division of Clinical Science, National Cancer Institute, Rockville, Maryland 20850 3300, USA
    Environ Health Perspect 105:935-9. 1997
    ..This is an area in which our growing understanding of lung cancer biology is providing clues on improving the inhibition of cancer progression...
  4. ncbi request reprint Differential expression of the early lung cancer detection marker, heterogeneous nuclear ribonucleoprotein-A2/B1 (hnRNP-A2/B1) in normal breast and neoplastic breast cancer
    J Zhou
    Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Breast Cancer Res Treat 66:217-24. 2001
    ..Expression of hnRNP-A2/B1 in breast cancer cells was decreased by exposure to retinoids coordinately with decreased cell growth. These results warrant further evaluation of hnRNP-A2/B1 as a marker of breast carcinogenesis...
  5. ncbi request reprint Biochemical characterization of peptide alpha-amidation enzyme activities of human neuroendocrine lung cancer cell lines
    A M Treston
    Intervention Section, National Cancer Institute Division of Cancer Prevention and Control, Rockville, Maryland 20850
    Cell Growth Differ 4:911-20. 1993
    ....
  6. ncbi request reprint Lipoxygenase inhibitors prevent lung carcinogenesis and inhibit non-small cell lung cancer growth
    T W Moody
    Cell and Cancer Biology Department, National Cancer Institute, Rockville, Maryland, USA
    Exp Lung Res 24:617-28. 1998
    ..These data indicate that lipoxygenase inhibitors inhibit lung cancer growth and prevent lung carcinogenesis...
  7. ncbi request reprint Moving to the routine management of pre symptomatic lung cancer
    J L Mulshine
    Intervention Section, Center for Cancer Research, NCI, NIH, Bethesda, MD 20850, USA
    Lung Cancer 34:S1-5. 2001
    ..A distillation of this process up to the current time is reviewed in this manuscript...
  8. ncbi request reprint Five-lipoxygenase inhibitors can mediate apoptosis in human breast cancer cell lines through complex eicosanoid interactions
    I Avis
    Intervention Section, Department of Cell and Cancer Biology, Division of Clinical Sciences, National Cancer Institute, NIH Clinical Center, 9000 Rockville Pike, Bethesda, MD 20892-1906, USA
    FASEB J 15:2007-9. 2001
    ....
  9. ncbi request reprint Reducing lung cancer risk: early detection
    J L Mulshine
    Department of Cell and Cancer Biology, Medicine Branch, Division of Clinical Science, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1906, USA
    Chest 116:493S-496S. 1999
    ....
  10. ncbi request reprint Expression of heterogeneous nuclear ribonucleoprotein A2/B1 changes with critical stages of mammalian lung development
    L M Montuenga
    Cell and Cancer Biology Department, Medicine Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Am J Respir Cell Mol Biol 19:554-62. 1998
    ....
  11. ncbi request reprint Antitumor activity of a monoclonal antibody directed against gastrin-releasing peptide in patients with small cell lung cancer
    M J Kelley
    Navy Medical Oncology Branch, National Cancer Institute, Bethesda, MD 20889 5105, USA
    Chest 112:256-61. 1997
    ..A phase 1 trial and pharmacokinetic modeling in patients with lung cancer has defined the phase 2 dose of 2A11 but the antitumor activity in patients is unknown...
  12. pmc Lung cancer. 2: screening and early diagnosis of lung cancer
    J L Mulshine
    Intervention Section, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892 1906, USA
    Thorax 57:1071-8. 2002
    ..Critical analyses of the nuances of this process are essential if the field is to move forward...
  13. ncbi request reprint Early lung cancer detection: approaching the 'tipping point'?
    James L Mulshine
    Rush University Medical School, Chicago, IL, USA
    Oncology (Williston Park) 20:1632. 2006
  14. ncbi request reprint Inhibitors of the arachidonic acid pathway and peroxisome proliferator-activated receptor ligands have superadditive effects on lung cancer growth inhibition
    Ingalill Avis
    Intervention Section, Cell and Cancer Biology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Cancer Res 65:4181-90. 2005
    ....
  15. ncbi request reprint Clinical practice. Lung cancer screening
    James L Mulshine
    Intervention Section, Cell and Cancer Biology Branch, Lung Cancer and Aerodigestive Chemoprevention Faculty, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    N Engl J Med 352:2714-20. 2005
  16. ncbi request reprint Early stage lung cancer--new approaches to evaluation and treatment: conference summary statement
    Thomas J Lynch
    Division of Hematology Oncology and Dana Farber Partners Cancer Care, Massachusetts General Hospital, 100 Blossom Street, Boston, MA 02114, USA
    Clin Cancer Res 11:4981s-4983s. 2005
  17. ncbi request reprint Clinical issues in the management of early lung cancer
    James L Mulshine
    Cell and Cancer Biology Branch, Center for Cancer Research, National Cancer Institute NIH, 9000 Rockville Pike, Bethesda, MD 20892 1906, USA
    Clin Cancer Res 11:4993s-4998s. 2005
    ..The rapid improvement in resolution and cost of spiral CT has provided a powerful impetus to reconsider the possibilities for achieving safe, economical, and meaningful early lung cancer detection...
  18. ncbi request reprint Current issues in lung cancer screening
    James L Mulshine
    Rush University Medical Center, Chicago, Illinois 60612, USA
    Oncology (Williston Park) 19:1724-30; discussion 1730-1. 2005
    ..We discuss recommendations from several organizations, such as the US Preventive Services Task Force and the American Cancer Society...
  19. ncbi request reprint Successful anti-cancer drug targets able to pass FDA review demonstrate the identifiable signature distinct from the signatures of random genes and initially proposed targets
    Anatoly L Mayburd
    CPA Global, LLC, 1725 Duke Street, Alexnadria, VA 22314, USA
    Bioinformatics 24:389-95. 2008
    ..Given these limitations, the current study was conducted to explore the classification features defining the therapeutic success that can result from targeting a particular gene...
  20. ncbi request reprint Ingenuity network-assisted transcription profiling: Identification of a new pharmacologic mechanism for MK886
    Anatoly L Mayburd
    Intervention Section, National Cancer Institute, NIH, Bethesda, MD 20859, USA
    Clin Cancer Res 12:1820-7. 2006
    ..The rate of lipid absorbance is generally higher for tumors, suggesting a promise of a targeted liposome-based delivery system for this drug. These results suggest a novel antitumor pharmacologic mechanism...
  21. ncbi request reprint Lung cancer screening
    Apar Kishor Ganti
    Division of Hematology Oncology, Department of Internal Medicine, University of Nebraska Medical Center, 987680 Nebraska Medical Center, Omaha, Nebraska 68198 7680, USA
    Oncologist 11:481-7. 2006
    ..Currently, the decision to screen for lung cancer should involve a careful discussion with the individuals involved about the potential advantages, costs, and drawbacks of the approach...
  22. ncbi request reprint Developing CT image-processing tools to accelerate progress in lung cancer drug development
    James L Mulshine
    Rush University Medical School Chicago, Illinois, USA
    Oncology (Williston Park) 20:1606, 1608-10, 1614 passim. 2006
  23. ncbi request reprint New developments in lung cancer screening
    James L Mulshine
    Cell and Cancer Biology Branch, National Institutes of Health, Building 10, Room 12N226, Bethesda, MD 20892 1906, USA
    J Clin Oncol 23:3198-202. 2005
    ....
  24. ncbi request reprint Screening for lung cancer: in pursuit of pre-metastatic disease
    James L Mulshine
    Intervention Section, Cell and Cancer Biology Branch, Center for Cancer Research, National Cancer Institute, National Institutes for Health, Bethesda, Maryland 20892 1906, USA
    Nat Rev Cancer 3:65-73. 2003
    ..More sensitive imaging tools might also provide a window into earlier biology, enabling the molecular dynamics of lung cancer progression to be elucidated...
  25. ncbi request reprint Surgical considerations with lung cancer screening
    Elizabeth E Warner
    J Surg Oncol 84:1-6. 2003
  26. ncbi request reprint Tobacco money: up in smoke?
    James L Mulshine
    Lancet 360:1979-80; author reply 1981. 2002
  27. ncbi request reprint Randomized, double-blind, placebo-controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia
    James L Mulshine
    Intervention Section, Cell and Cancer Biology Branch, Department of Pathology and Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 1906, USA
    Clin Cancer Res 10:1565-73. 2004
    ..This trial evaluated if a topically delivered oral rinse containing ketorolac was as safe as and more effective than oral rinse alone in reducing the area of oral leukoplakia...
  28. ncbi request reprint Lung cancer screening with spiral CT: toward a working strategy
    Elizabeth E Warner
    Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
    Oncology (Williston Park) 18:564-75, discussion 578, 583-4, 587. 2004
    ..We also explore the current standards of early lung cancer management and target areas where potential pitfalls and opportunities for improvement exist...
  29. ncbi request reprint Is the gene expression pattern of lung cancer detected by screening with spiral computed tomography different from that of symptom-detected lung cancer?
    James L Mulshine
    Clin Cancer Res 10:5973-4. 2004
  30. ncbi request reprint Epithelial-directed drug delivery: influence of formulation and delivery devices
    James L Mulshine
    Department of Health and Human Services, Cell and Cancer Biology Branch, Center for Cancer Research, National Cancer Institute, National Institutes for Health, Room 12N226, Bethesda, MD 20892 1906, USA
    Lung Cancer 46:387-92. 2004
    ..The questions considered in this forum is whether improvements in these areas are sufficiently mature to allow application of local regional drug delivery with targeted drug agents to improve the management of early lung cancer...
  31. ncbi request reprint Screening of mutations in the ras family of oncogenes by polymerase chain reaction-based ligase chain reaction
    Alfredo Martinez
    Intervention Section, Department of Cell and Cancer Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Methods Mol Med 74:187-200. 2003
  32. ncbi request reprint cDNA expression profiling reveals elevated gene expression in cell clusters overlying focally disrupted myoepithelial cell layers: implications for breast tumor invasion
    Yan Gao Man
    Department of Gynecologic and Breast Pathology, Armed Forces Institute of Pathology and American Registry of Pathology, 6825 16th Street, NW, Washington, DC 20306 6000, USA
    Breast Cancer Res Treat 89:199-208. 2005
    ..This study attempted to assess whether these cells also had a different expression profile on tumor progression related genes...
  33. ncbi request reprint Radiologic screening for lung cancer
    Gorka Bastarrika
    Department of Radiology, Clinica Universitaria, Facultad de Medicina, Universidad de Navarra, Pamplona, Spain
    Expert Rev Anticancer Ther 2:385-92. 2002
    ..Preliminary results are promising but the outstanding question is whether the magnitude of improvement is sufficient to affect a measurable reduction in lung cancer mortality?..
  34. ncbi request reprint Chemoprevention of head and neck cancer
    James L Mulshine
    Rush University Medical Center, USA
    Clin Adv Hematol Oncol 3:763-5. 2005
  35. ncbi request reprint A subset of in situ breast tumor cell clusters lacks expression of proliferation and progression related markers but shows signs of stromal and vascular invasion
    Yan Gao Man
    Department of Gynecologic and Breast Pathology, Armed Forces Institute of Pathology and American Registry of Pathology, 6825 16th Street, NW, Washington, DC 20306 6000, USA
    Cancer Detect Prev 29:323-31. 2005
    ..The purpose of this study was to further elucidate the immunohistochemical and morphological profiles of these ER NCC...
  36. ncbi request reprint The potential contributions of chronic inflammation to lung carcinogenesis
    Santiago Ballaz
    Department of Histology and Pathology, Center for Applied Medical Research, University of Navarra, Pamplona, Spain
    Clin Lung Cancer 5:46-62. 2003
    ....
  37. doi request reprint Commentary: lung cancer screening--progress or peril
    James L Mulshine
    Rush University Medical Center, 1735 West Harrison Street, Suite 206, Chicago, Illinois 60612 3823, USA
    Oncologist 13:435-8. 2008